Parameter
| Biomarker | GFAP | Full name | Glial Fibrillary Acidic Protein | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Pathological Confirmation, Prognosis |
| Disease | Frontotemporal Dementia | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Plasma/CSF (SIMOA, Immunoassay) | ||
| Pathobiological Mechanisms | Released after astrocyte activation, reflecting blood-brain barrier injury and neuroinflammation. | ||||
| Clinical Availability Status | Research validation stage | ||||
| Notes and Dynamics | Plasma GFAP in AD patients is 35% higher than in FTD, distinguishing AD from bvFTD; CSF GFAP is elevated 1 year before symptoms in GRN mutation carriers. | ||||